Abeona Therapeutics Inc. ABEO
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
Abeona Therapeutics Inc. (ABEO) is a healthcare company listed in the US with a market value of about $138M. In the twelve months to September 30, 2026 it had revenue of $39M and net income of -$63M, a net margin of -160.3%.
Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -112%.
About Abeona Therapeutics
Abeona Therapeutics is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $925000 in 2014 to $4M in 2023, growth of about 15.9% a year. It was profitable in 1 of the last 10 years in our data. Its share count rose by 741% over three years (dilution for shareholders).
Score: 0.8 / 5
Checks passed
- Strong R&D investment or growth above 20%
- ROE above 15%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $39M | — | — | $4M | $1M | $3M | $10M | — | $3M | $837000 | $2M |
| Net income | -$63M | $71M | -$64M | -$54M | -$40M | -$85M | -$84M | -$76M | -$57M | -$27M | -$22M |
| Free cash flow | -$66M | -$84M | -$58M | -$37M | -$44M | -$70M | -$36M | -$69M | -$48M | -$24M | -$14M |
| EPS (diluted) | $-1.07 | $1.01 | $-1.55 | $-2.53 | $-5.53 | $-0.86 | $-0.91 | $-1.51 | $-1.19 | $-0.66 | $-0.64 |
| Net margin | -160.3% | — | — | -1548.2% | -2807.4% | -2831.2% | -842.3% | — | -1890.3% | -3263.9% | -931.6% |
| ROIC | — | -48.5% | -75.6% | -184.1% | -117.0% | -137.2% | -58.7% | -32.7% | -34.3% | -12.9% | -19.0% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does Abeona Therapeutics pay a dividend?
Not currently.
Is Abeona Therapeutics a good stock to buy?
We do not give buy or sell advice. Abeona Therapeutics scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.